Neurology 2003;60:1378-1381
© 2003 American Academy of Neurology
Brief Communications
New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism
N. Rawal, MS,
M. Periquet, MS,
E. Lohmann, MD,
C.B. Lücking, MD,
H.A. Teive, MD,
G. Ambrosio, MD,
S. Raskin, MD,
S. Lincoln, BS,
N. Hattori, MD,
J. Guimaraes, MD,
M.W.I.M. Horstink, MD,
W. Dos Santos Bele, PhD,
E. Brousolle, MD,
A. Destée, MD,
Y. Mizuno, MD,
M. Farrer, PhD,
J.-F. Deleuze, PhD,
G. De Michele, MD,
Y. Agid, MD PhD,
A. Dürr, MD PhD and
A. Brice, MD for The French Parkinsons Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinsons Disease*
* See the Appendix for a list of The French Parkinsons Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinsons Disease group members.
Address correspondence and reprint requests to Dr. Alexis Brice, INSERM U289, Hôpital de la Salpêtrière, 47, Boulevard de LHôpital, 75013 Paris, France; e-mail: brice{at}ccr.jussieu.fr
The frequency of parkin mutations was evaluated in 30 families of highly diverse geographic origin with early-onset autosomal recessive parkinsonism. Twelve different mutations, six of which were new, were found in 10 families from Europe and Brazil. Patients with parkin mutations had significantly longer disease duration than patients without the mutation but with similar severity of disease, suggesting a slower disease course. Two patients with parkin mutations had atypical clinical presentation at onset, with predominant tremor when standing.
This article has been cited by other articles:

|
 |

|
 |
 
I. H. Henn, L. Bouman, J. S. Schlehe, A. Schlierf, J. E. Schramm, E. Wegener, K. Nakaso, C. Culmsee, B. Berninger, D. Krappmann, et al.
Parkin Mediates Neuroprotection through Activation of I{kappa}B Kinase/Nuclear Factor-{kappa}B Signaling
J. Neurosci.,
February 21, 2007;
27(8):
1868 - 1878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hampe, H. Ardila-Osorio, M. Fournier, A. Brice, and O. Corti
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity
Hum. Mol. Genet.,
July 1, 2006;
15(13):
2059 - 2075.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Sriram, X. Li, H. S. Ko, K. K.K. Chung, E. Wong, K. L. Lim, V. L. Dawson, and T. M. Dawson
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin
Hum. Mol. Genet.,
September 1, 2005;
14(17):
2571 - 2586.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Azher and J. Jankovic
Camptocormia: Pathogenesis, classification, and response to therapy
Neurology,
August 9, 2005;
65(3):
355 - 359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. F. Mata, P. J. Lockhart, and M. J. Farrer
Parkin genetics: one model for Parkinson's disease
Hum. Mol. Genet.,
April 1, 2004;
13(90001):
R127 - 133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. E. Morrison
Parkin mutations and early onset parkinsonism
Brain,
June 1, 2003;
126(6):
1250 - 1251.
[Full Text]
[PDF]
|
 |
|
|